Cisplatin º´ÇÕÈÇпä¹ý½Ã ±Þ¼º Ç×±¸ÅäÈ¿°ú¿¡ ´ëÇÑ Tropisetron°ú OndansetronÀÇ ºñ±³
A Comparison of the Acute Antiemetic Effect of Tropisetron with Ondansetron in Patients Receiving Cisplatin
¼Ò¼Ó »ó¼¼Á¤º¸
Á¶¼ºÅÂ
Ȳº¸±Ç/±èÂù±Ô/°íºÀ¹Î/¹è¼ºÇÑ/ºÀÁ¾´ë/ÀÌö¿ì/¹Ú¼º±Ô/¿øÁ¾È£
KMID : 0360319980300061240
Abstract
¼·Ð
½ÉÇÑ ¿À½É°ú ±¸Åä´Â Ç×¾ÏÁ¦ Åõ¿©µµÁß È¯ÀÚ°¡ °æÇèÇϰԵǴ °¡Àå ÈçÇÏ°í °íÅ뽺·¯¿î ºÎÀÛ
¿ëÀ̸ç, ȯÀÚ·Î ÇÏ¿©±Ý Áö¼ÓÀûÀÎ Ç×¾ÏÁ¦ Åõ¿©¸¦ °ÅºÎÇÏ°Ô ¸¸µå´Â °¡Àå Áß¿äÇÑ ÀÎÀÚÀÌ´Ù. Ư
È÷ cisplatinÀº Ç×¾ÏÁ¦ Áß °¡Àå ½ÉÇÏ°Ô ¿À½É°ú ±¸Å並 À¯¹ßÇÏ¸ç ¿À½É°ú ±¸Å並 ¿¹¹æÇϴ ó
Ä¡¸¦ ½ÃÇàÇÏÁö ¾ÊÀ¸¸é ´ëºÎºÐÀÇ È¯ÀÚ°¡ ½ÉÇÑ ±¸Å並 °æÇèÇÑ´Ù. Ç×¾ÏÈÇпä¹ý¿¡ ÀÇÇØ À¯¹ßµÇ
´Â ±¸Åä´Â ¼ÒÀåÀÇ Å©·Òģȼº ¼¼Æ÷¿¡¼ À¯¸®µÇ´Â serotonin(ÀÌÇÏ 5-HT)ÀÌ vagal afferent
fiber, ¶Ç´Â ÁßÃ߽Űæ°èÀÇ area postrema µî¿¡ ÀÖ´Â 5-HT3 ¼ö¿ëü¿¡ °áÇÕÇÏ
¿© ¹ß»ýÇÑ´Ù. °í¿ë·®ÀÇ cisplatinÀ» Æ÷ÇÔÇÏ´Â Ç×¾ÏÈÇпä¹ý¿¡¼ Ç×±¸ÅäÈ¿°ú¸¦ À§ÇÏ¿© ÀÓ»óÀû
À¸·Î metoclopropamide, dexamethasone, lorazepam º´ÇÕ¿ä¹ý(ÀÌÇÏ MDLº´ÇÕ¿ä¹ý)ÀÌ °ú°Å¿¡
³Î¸® »ç¿ëµÇ¾úÀ¸³ª, ÃÖ±Ù 5-HT ¼ö¿ëü¿¡ ¼±ÅÃÀûÀ¸·Î ±æÇ×ÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾àÁ¦ÀÇ ³ôÀº Ç×
±¸ÅäÈ¿°ú°¡ ÀÎÁ¤µÇ¸é¼ ÀÓ»ó¿¡¼ ³Î¸® »ç¿ëµÇ°í ÀÖ´Ù. 5-HT ¼ö¿ëü ±æÇ×Á¦´Â MDLº´ÇÕ¿ä
¹ý¿¡ ºñÇØ Ãßü¿Ü·Î Áõ»óÀ̳ª ÁøÁ¤ÀÛ¿ë µîÀÇ ºÎÀÛ¿ëÀÌ °ÅÀÇ ¾øÀ¸¸é¼ Ç×±¸ÅäÈ¿°ú¿¡ Â÷ÀÌ°¡
¾ø¾î, Ç×¾ÏÈÇпä¹ý, ƯÈ÷ °í¿ë·®ÀÇ cisplatinÀ» Æ÷ÇÔÇÏ´Â ÈÇпä¹ý¿¡¼ Ç×±¸ÅäÁ¦·Î½á MDL
º´ÇÕ¿ä¹ýÀ» ´ëÄ¡ÇÏ°í ÀÖ´Ù. ÇöÀç ÀÓ»óÀûÀ¸·Î ³Î¸® »ç¿ëµÇ´Â 5-HT ¼ö¿ëü ±æÇ×Á¦·Î´Â
ondansetron, granisetron, tropisetron µîÀÌ ÀÖ´Ù. ÀúÀÚµéÀº °í¿ë·®ÀÇ cisplatinÀ» Æ÷ÇÔÇÏ´Â Ç×
¾ÏÈÇпä¹ý¿¡¼ 5-HT3 ¼ö¿ëü ±æÇ×Á¦ÀÎ tropisetron°ú ondansetronÀÇ Ç×±¸Åä
È¿°ú¸¦ ºñ±³ÇÏ°íÀÚ ÇÏ¿´´Ù.
Purpose : Tropisetron, a new specific 5-hydroxytryptamine3 (5-HT3)
receptor antagonist, is an effective antiemetic agent in the control of chemotherapy
induced emesis with a long half life and bioavailablity. We compared the efficacy and
safefy of Tropisetron and ondansetron to control emesis induced by highly emetogenic
chemotherapeutics (cisplatin¡Ã50 §·/m2).
Materials and Methods : Twenty-one patients were administered in a randomized, open,
cross-over study and received either tropisetron plus dexamethasone or ondansetron plus
dexamethasone during two successive cycles of chemotherapy.
Results : Control of acute emesis with either tropisetron or ondansetron was 100% vs
95.2%, and 80.9% vs 76.2% in control of delayed emesis. Both severity and duration of
nausea showed no statistically significant difference between tropisetron and ondansetron.
Poor appetite and headache were most common side effects in both groups.
Conclusion : There was no significant difference in efficacy for control of emesis and
nausea between tropisetron and ondansetron in cisplatin-based chemotherapy.
Å°¿öµå
Tropisetron; Ondansetron; Cisplatin; Emesis;
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸